AUG 01, 2019 9:59 PM PDT

A Safer Cannabis Extract Could Help Users Fight Cannabis Dependence

WRITTEN BY: C Reardon

According to The National Institute on Drug Abuse, roughly 30% of recreational cannabis users in the U.S. may be at risk of having some degree of cannabis use disorder resulting in symptoms of dependence. Dependence often manifests in irritability, changes in appetite, and poor sleep patterns. The UN Office on Drugs and Crime says that cannabis is the most widely used psychoactive substance used and accounts for the largest number of people dependent on illicit drugs globally.

In a study on the likelihood of developing an alcohol and cannabis use disorder during youth, it was found that those who begin using marijuana regularly before the age of 18 are four to seven times more likely to develop a marijuana use disorder than adult users. 

Marijuana use disorder turns into addiction when a user cannot stop using the drug even though it interferes with daily life. Estimating the number of people addicted to marijuana can be controversial, mainly because epidemiological studies of substance use often use dependence as a substitute for addiction. However, it is possible to be dependent without being addicted.

In a recent study, researchers from the University of Sydney and the New South Wales Ministry of Health in Australia tested a new medicinal drug called Nabiximols for the treatment of cannabis dependence. This was a randomized clinical trial consisting of 128 participants who were all recreational cannabis users. The participants were monitored over 12 weeks, and only some of them were given the actual drug, administered in spray form, orally, under the tongue. The researchers gave each participant an average dose of 18 sprays per day; each spray was 0.1 milliliters, containing 2.7 milligrams (mg) of THC and 2.5 mg of CBD.

Photo Source: MEL Magazine 

The research found that Nabiximols, a cannabinoid agonist drug, made up of a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC), resulted in fewer days of illicit cannabis use in patients who received the drug compared to those who received a placebo. 

This cannabinoid agonist, consisting of a cannabis extract, works through interaction with the body's cannabinoid receptors. Cannabinoid receptors are part of the endocannabinoid system, which is involved in a variety of physiological processes including appetite, pain-sensation, mood, and memory. Through targeting these receptors researchers hope to reduce the rate of relapse in those seeking help for cannabis dependence. 

"The principles are very similar to nicotine replacement; you are providing patients with a medicine, which is safer than the drug they're already using and linking this with medical and counseling support to help people address their illicit cannabis use," Prof. Lintzeris, lead author on the study, explains.

Currently, four out of five patients relapse to regular cannabis use within six months of medical or psychological interventions.

 

About the Author
  • Chelsey is a content strategist and copywriter with a business degree. She has a background in public relations and marketing and enjoys writing about various topics, from health, to lifestyle, to women’s issues. Since 2016, she has written for a variety of online publications, earning well over 100,000 shares. She published her first book in 2019.
You May Also Like
AUG 24, 2021
Drug Discovery & Development
A comparison of drugs for relapsing-remitting multiple sclerosis.
AUG 24, 2021
A comparison of drugs for relapsing-remitting multiple sclerosis.
     Multiple sclerosis (MS) is a rare and unpredictable autoimmune disease in which the body’s inn ...
AUG 28, 2021
Neuroscience
Virtual Reality Reduces Pain in Children During Medical Procedures
AUG 28, 2021
Virtual Reality Reduces Pain in Children During Medical Procedures
Virtual reality (VR) reduces pain and anxiety in children undergoing medical procedures. The corresponding study was pub ...
AUG 30, 2021
Cell & Molecular Biology
A CRISPR-Cas to Target RNA Viruses
AUG 30, 2021
A CRISPR-Cas to Target RNA Viruses
The microbes of the world are constantly competing with one another. There are viruses that can infect bacteria, called ...
SEP 01, 2021
Coronavirus
It Seems Not All COVID-19 Patients Develop Antibodies
SEP 01, 2021
It Seems Not All COVID-19 Patients Develop Antibodies
It's been generally assumed that people who get infected with SARS-COV-2 will develop antibodies to the virus, which cau ...
SEP 01, 2021
Genetics & Genomics
Do Some Friendships Have a Genetic Basis?
SEP 01, 2021
Do Some Friendships Have a Genetic Basis?
Have you ever felt an instantaneous connection with someone you just met? New research has suggested that there may be a ...
SEP 09, 2021
Cancer
Can a Mole Fight Melanoma?
SEP 09, 2021
Can a Mole Fight Melanoma?
About 30% of melanoma cases arise from an existing nevus.  More commonly known as moles, Nevi are skin growths that ...
Loading Comments...